Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.43 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1634308 | 0.78 | KMT2A (0.49) | MEN1KMT2ASCN2APIM3HIPK4 | |
| SCHEMBL1633789 | 0.74 | MEN1 (0.45) | MEN1KMT2ASCN2APIM3HIPK4 | |
| SCHEMBL1635525 | 0.73 | SCN2A (0.54) | MEN1KMT2ASCN2APIM3HIPK4 | |
| SCHEMBL19667872 | 0.70 | KMT2A (0.58) | MEN1KMT2ASCN2ACA9CA12 | |
| SCHEMBL1634168 | 0.69 | NR1H3 (0.53) | MEN1KMT2ASCN2APIM3HIPK4 | |
| SCHEMBL4649471 | 0.68 | KMT2A (0.78) | MEN1KMT2ASCN2ACA9CA12 | |
| SCHEMBL725608 | 0.66 | NR1H3 (0.67) | MEN1KMT2ASCN2APIM3HIPK4 | |
| SCHEMBL19667878 | 0.66 | POLB (0.50) | MEN1KMT2ANR1H3POLB | |
| SCHEMBL7360730 | 0.66 | SCN2A (0.62) | MEN1KMT2ASCN2APIM3HIPK4 | |
| SCHEMBL21585233 | 0.64 | KMT2A (0.59) | MEN1KMT2ASCN2ACA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932416-B2 | Prepared by electrophilic aromatic substitution via halogenation, chlorosulfonation or nitration of a pentafluorosulfanylbenzene; 2-Methyl-5-nitro-4-pentafluorosulfuranylbenzoic acid; for liquid crystals, polymers, pesticides, herbicides, fungicides, nematocides, parasiticides, insecticides, acaricides | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-04-26 | — | — | US | disclosed |
| US-7932416-B2 | Prepared by electrophilic aromatic substitution via halogenation, chlorosulfonation or nitration of a pentafluorosulfanylbenzene; 2-Methyl-5-nitro-4-pentafluorosulfuranylbenzoic acid; for liquid crystals, polymers, pesticides, herbicides, fungicides, nematocides, parasiticides, insecticides, acaricides | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-04-26 | — | — | US | disclosed |
| US-7932416-B2 | Prepared by electrophilic aromatic substitution via halogenation, chlorosulfonation or nitration of a pentafluorosulfanylbenzene; 2-Methyl-5-nitro-4-pentafluorosulfuranylbenzoic acid; for liquid crystals, polymers, pesticides, herbicides, fungicides, nematocides, parasiticides, insecticides, acaricides | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-04-26 | — | — | US | disclosed |
| US-20080091031-A1 | Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates | SANOFI-AVENTIS DEUTSCHLAND GMBH (FR) | 2008-04-17 | — | — | US | disclosed |
| US-20080091031-A1 | Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates | SANOFI-AVENTIS DEUTSCHLAND GMBH (FR) | 2008-04-17 | — | — | US | disclosed |
| US-20080091031-A1 | Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates | SANOFI-AVENTIS DEUTSCHLAND GMBH (FR) | 2008-04-17 | — | — | US | disclosed |
| US-7317124-B2 | Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-01-08 | — | — | US | disclosed |
| US-7317124-B2 | Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-01-08 | — | — | US | disclosed |
| US-7317124-B2 | Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-01-08 | — | — | US | disclosed |
| US-20050148652-A1 | Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148652-A1 | Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates | PFAS, DDT, PNPO | MEN1 2796/4885KMT2A 3620/4885SCN2A 3950/4885 |
| US-20080091031-A1 | Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates | PFAS, DDT, PNPO | MEN1 2796/4885KMT2A 3620/4885SCN2A 3950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.